Clinical Trials Logo

Clinical Trial Summary

D0: inclusion visit - information - Realization of the ocular ultrasound (care) - Collection of consent - Realization of high resolution MRI with injection of contrast product (duration of 30 minutes) For the realization of the MRI, the contrast product used is the gadobutrol. The dose, the lowest allowing an enhancement of sufficient contrast for diagnostic purposes (0.1 mmol/kg body mass body), is administered as a bolus intravenously in the lying patient. The MRI examination can begin immediately after injection. The patient should be monitored for at least half an hour after this, the majority of undesirable effects occurring at the during this period. The indication of ocular ultrasound and ophthalmological follow-up of the patient up to 1 month after inclusion will be collected at from their medical records.


Clinical Trial Description

D0: inclusion visit - information - Realization of the ocular ultrasound (care) - Collection of consent - Realization of high resolution MRI with injection of contrast product (duration of 30 minutes) For the realization of the MRI, the contrast product used is the gadobutrol. The dose, the lowest allowing an enhancement of sufficient contrast for diagnostic purposes (0.1 mmol/kg body mass body), is administered as a bolus intravenously in the lying patient. The MRI examination can begin immediately after injection. The patient should be monitored for at least half an hour after this, the majority of undesirable effects occurring at the during this period. The indication of ocular ultrasound and ophthalmological follow-up of the patient up to 1 month after inclusion will be collected at from their medical records. ;


Study Design


NCT number NCT05300698
Study type Observational
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact Amélie Yavchitz, PhD
Phone 0148036454
Email ayavchitz@for.paris
Status Recruiting
Phase
Start date January 23, 2024
Completion date November 2026